Zepbound Alternatives & Comparison

One head-to-head settles the weight question and does not settle the whole question. SURMOUNT-5 put Zepbound at −20.2% against Wegovy's −13.7% at 72 weeks, a 6.5-point gap under one protocol. Wegovy answers a different question: SELECT cut major cardiovascular events 20%, and Zepbound's SURPASS-CVOT does not read out until 2027. Cash pricing is a wash at $349–$499. So the honest split is magnitude of weight loss against proven event reduction — and that is a prescriber's call, not a table's.

One molecule, one dose ladder, one maker, sold twice under two names. Diabetes sits on the Mounjaro label; obesity and sleep apnea sit on Zepbound's. Pricing is identical at $349 starter and $499 maintenance for vials. The practical difference is which label your prescription is written against, because that is what decides coverage. Nothing pharmacological separates them, and any page implying otherwise is selling something.

A daily liraglutide injection against a weekly dual agonist, and there is not much contest on either axis a buyer cares about. Zepbound runs $349–$499 through LillyDirect. Saxenda has no cash-pay tier of its own and lists near $1,400. Saxenda's residual argument is availability — it has been on the market since 2014 and is sometimes covered where newer drugs are excluded, which is a formulary fact rather than a clinical one.

The strongest injectable against the first non-peptide pill. SURMOUNT-1 reported −20.9% at 72 weeks for Zepbound; ATTAIN-1 reported −11.1% at 72 weeks for Foundayo — different trials, but both at 72 weeks in obesity, which makes the comparison unusually readable for a cross-trial one. Neither has published cardiovascular outcomes. Zepbound is $349–$499 through LillyDirect; Foundayo's direct-pay tier is still rolling out. Roughly: more weight loss, or no needle and no cold chain.

SURMOUNT-1 reported −20.9% at 72 weeks for Zepbound; COR-I reported −6.1% at 56 weeks for Contrave at full dose. The cost runs the other way — about $99 a month through Currax against $349–$499 through LillyDirect. Contrave is oral, cheap, and frequently the step-therapy hurdle standing in front of the drug you asked for, which is the practical reason to understand what it does before dismissing it.

About −20.9% at 72 weeks for Zepbound in SURMOUNT-1 against roughly −10.9% at 56 weeks for Qsymia in EQUIP, or −9.8% in CONQUER. Zepbound is $349–$499 through LillyDirect; Qsymia is $100–$200, and generic phentermine plus topiramate around $50. Half the effect for a fifth of the price is a real trade rather than a joke — and for someone paying cash indefinitely, it is the trade the arithmetic often favors.